Acadia Pharmaceuticals Announces Continued Improvements In RSBQ And CGI-I Scores With Long-Term DAYBUE Treatment In Phase 3 LAVENDER And LILAC Studies; DAYBUE Safety Profile Consistent With LAVENDER Trial Findings; Published Results Show Improved Rett Symptoms In Patients Completing LILAC-1 And LILAC-2 Open-Label Extension Studies
Portfolio Pulse from Benzinga Newsdesk
Acadia Pharmaceuticals announced continued improvements in RSBQ and CGI-I scores with long-term DAYBUE treatment in Phase 3 LAVENDER and LILAC studies. The safety profile of DAYBUE remains consistent with previous findings, and published results show improved Rett symptoms in patients completing LILAC-1 and LILAC-2 open-label extension studies.
July 18, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acadia Pharmaceuticals announced positive long-term results for DAYBUE in Phase 3 LAVENDER and LILAC studies, showing continued improvements in RSBQ and CGI-I scores and a consistent safety profile.
The announcement of continued improvements in key clinical scores and a consistent safety profile for DAYBUE in long-term studies is likely to boost investor confidence in Acadia Pharmaceuticals. Positive clinical trial results often lead to stock price increases, especially when they pertain to treatments for conditions with high unmet medical needs like Rett syndrome.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100